Genetic polymorphisms of xeroderma pigmentosum group D and prostate cancer risk: A meta-analysis

Journal of Cancer Research and Therapeutics

Volumn 9, Issue 2, 2013, Pages 187-192

  Zhu, Hongcheng ^a   Cao, Songyu ^a   Liu, Yun ^a   Ding, Xiangxiang ^a   Wu, Qianqian ^a   Ma, Hongxia ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Excision repair cross complementing gene 2; meta analysis; polymorphism; prostate cancer; xeroderma pigmentosum group D

Indexed keywords

XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ALLELE; ASIAN; CANCER RISK; CAUCASIAN; EMBASE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MEDLINE; META ANALYSIS; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84880089237     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.113345     Document Type: Review

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85
3. Pathak SK, Sharma RA, Steward WP, Mellon JK, Griffiths TR, Gescher AJ. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: Targets for chemopreventive strategies. Eur J Cancer 2005;41:61-70
4. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282:125-36
5. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J 2003;17:1195-214
6. Sikka SC. Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention-A mechanistic approach. Curr Med Chem 2003;10:2679-92
7. Bau DT, Wu HC, Chiu CF, Lin CC, Hsu CM, Wang CL, et al. Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res 2007;27:2893-6
8. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: An update. Toxicology 2003;193:3-34
9. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and lung cancer: A HuGE review. Am J Epidemiol 2005;161:1-14
10. Fuss JO, Tainer JA. XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. DNA Repair (Amst) 2011;10:697-713
11. Wang Z, Svejstrup JQ, Feaver WJ, Wu X, Kornberg RD, Friedberg EC. Transcription factor b (TFIIH) is required during nucleotide-excision repair in yeast. Nature 1994;368:74-6
12. Drapkin R, Reardon JT, Ansari A, Huang JC, Zawel L, Ahn K, et al. Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature 1994;368:769-72
13. Taylor EM, Broughton BC, Botta E, Stefanini M, Sarasin A, Jaspers NG, et al. Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc Natl Acad Sci U S A 1997;94:8658-63
14. Rzeszowska-Wolny J, Polanska J, Pietrowska M, Palyvoda O, Jaworska J, Butkiewicz D, et al. Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res 2005;164:132-40
15. Affatato AA, Wolfe KJ, Lopez MS, Hallberg C, Ammenheuser MM, Abdel-Rahman SZ. Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. Environ Mol Mutagen 2004;44:65-73
16. Mechanic LE, Marrogi AJ, Welsh JA, Bowman ED, Khan MA, Enewold L, et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2005;26:597-604
17. Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol Carcinog 2006;45:715-9
18. Suárez-Martínez EB, Ruiz A, Matías J, Morales L, Cruz A, Vázquez D, et al. Early-onset of sporadic basal-cell carcinoma: Germline mutations in the TP53, PTCH, and XPD genes. P R Health Sci J 2007;26:349-54
19. Wang F, Chang D, Hu FL, Sui H, Han B, Li DD, et al. DNA repair gene XPD polymorphisms and cancer risk: A meta-analysis based on 56 casecontrol studies. Cancer Epidemiol Biomarkers Prev 2008;17:507-17
20. Stern MC, Johnson LR, Bell DA, Taylor JA. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1004-11
21. Sreeja L, Syamala VS, Syamala V, Hariharan S, Raveendran PB, Vijayalekshmi RV, et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol 2008;134:645-52
22. De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res 2007;631:101-10
23. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:23-9
24. Mandal RK, Gangwar R, Mandhani A, Mittal RD. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: A study from North India. DNA Cell Biol 2010;29:183-90
25. Dhillon VS, Yeoh E, Fenech M. DNA repair gene polymorphisms and prostate cancer risk in South Australia-Results of a pilot study. Urol Oncol 2011;29:641-6
26. Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL. Genetic variation in DNA repair genes and prostate cancer risk: Results from a population-based study. Cancer Causes Control 2010;21:289-300
27. Lavender NA, Komolafe OO, Benford M, Brock G, Moore JH, Vancleave TT, et al. No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate 2010;70:113-9
28. Ritchey JD, Huang WY, Chokkalingam AP, Gao YT, Deng J, Levine P, et al. Genetic variants of DNA repair genes and prostate cancer: A population-based study. Cancer Epidemiol Biomarkers Prev 2005;14:1703-9
29. Gao R, Price DK, Dahut WL, Reed E, Figg WD. Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther 2010;10:13-8
30. Sobti RC, Berhane N, Melese S, Mahdi SA, Gupta L, Thakur H, et al. Impact of XPD gene polymorphism on risk of prostate cancer on north Indian population. Mol Cell Biochem 2012;362:263-8
31. Schaid DJ, Jacobsen SJ. Biased tests of association: Comparisons of allele frequencies when departing from Hardy-Weinberg proportions. Am J Epidemiol 1999;149:706-11
32. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48
33. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
34. Yuan L, Cui D, Zhao EJ, Jia CZ, Wang LD, Lu WQ. XPD Lys751Gln polymorphism and esophageal cancer risk: A meta-analysis involving 2288 cases and 4096 controls. World J Gastroenterol 2011;17:2343-8
35. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993;365:852-5
36. Pavanello S, Pulliero A, Siwinska E, Mielzynska D, Clonfero E. Reduced nucleotide excision repair and GSTM1-null genotypes influence anti-B a PDE-DNA adduct levels in mononuclear white blood cells of highly PAH-exposed coke oven workers. Carcinogenesis 2005;26:169-75
37. Zhang Y, Ding D, Wang X, Zhu Z, Huang M, He X. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms andcolorectal cancer risk: A meta-analysis of case-control studies. Int J Colorectal Dis 2011;26:1257-64
38. Zhan P, Wang Q, Wei SZ, Wang J, Qian Q, Yu LK, et al. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: A meta-analysis involving 22 case-control studies. J Thorac Oncol 2010;5:1337-45
39. Zhang J, Qiu LX, Leaw SJ, Hu XC, Chang JH. The association between XPD Asp312Asn polymorphism and lung cancer risk: A meta-analysis including 16,949 subjects. Med Oncol 2011;28:655-60
40. Li C, Jiang Z, Liu X. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: A meta-analysis. Mol Biol Rep 2010;37:301-9
41. Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer. Breast Cancer Res Treat 2010;124:531-41 Institutions